Case Reports in Dermatology最新文献

The First Case of Eruptive Pyogenic Granuloma following COVID-19 Vaccination. 首例接种 COVID-19 疫苗后出现爆发性化脓性肉芽肿的病例。

IF 0.9

Case Reports in Dermatology Pub Date : 2024-07-15 eCollection Date: 2024-01-01 DOI: 10.1159/000539849

Saman Al-Zahawi, Alireza Ghanadan, Fatema Saberi, Kamran Balighi, Zahra Razavi

引用次数: 0

A Challenging Case of Reactive Angioendotheliomatosis. 反应性血管内皮瘤病的棘手病例

IF 0.9

Case Reports in Dermatology Pub Date : 2024-07-05 eCollection Date: 2024-01-01 DOI: 10.1159/000539775

Georgios Kravvas, Lola Meghoma, Victoria Vilenchik, Jon Oxley, Daniel J Keith

{"title":"A Challenging Case of Reactive Angioendotheliomatosis.","authors":"Georgios Kravvas, Lola Meghoma, Victoria Vilenchik, Jon Oxley, Daniel J Keith","doi":"10.1159/000539775","DOIUrl":"10.1159/000539775","url":null,"abstract":"Introduction: Reactive angioendotheliomatosis (RAE) is a rare, benign, angioproliferative disorder with poorly understood aetiopathogenesis. It is characterised by vascular occlusion that occurs in patients with coexistent systemic or autoimmune disease.Case presentation: A 60-year-old female presented with an 8-week history of a painful, non-healing, and non-traumatic ulcer on the left thigh. Her past medical history included smoking, peripheral vascular disease (PVD) and previously treated rectal squamous cell carcinoma. The diagnosis of pyoderma gangrenosum with superimposed cellulitis was considered and treatment with oral antibiotics was initiated. Following failure to improve, a biopsy was undertaken leading to the diagnosis of RAE. The patient was referred for urgent consideration of surgical correction of PVD, but was deemed unsuitable for surgical treatment due to a poor performance status. The patient was treated with conservative measures, but her condition rapidly deteriorated and she passed away a few weeks later.Conclusion: RAE is notorious for mimicking a wide spectrum of diseases. It is an important differential diagnosis to consider in patients with non-healing ulceration and underlying systemic or autoimmune disorders. Our case raises awareness of this rare condition and the mortality that it carries if left untreated. In an attempt to reverse disease progression and mortality, we urge clinicians to attempt surgical correction of PVD even when faced with multiple comorbidities and poor performance status.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multisystem Langerhans Cell Histiocytosis following Treatment of Initially Presumed Atopic Dermatitis with Dupilumab: A Case Report of an Extremely Confusing Scenario. 用杜匹单抗治疗最初假定的特应性皮炎后出现的多系统朗格汉斯细胞组织细胞增生症：极易混淆的病例报告。

IF 0.9

Case Reports in Dermatology Pub Date : 2024-07-01 eCollection Date: 2024-01-01 DOI: 10.1159/000539704

Wenhao Cheng, Hong Ren, Wenlong Hu

引用次数: 0

Hedgehog Pathway and Programmed Cell Death Protein-1 Inhibitors for Advanced Basal Cell Carcinoma. 治疗晚期基底细胞癌的刺猬蛋白通路和程序性细胞死亡蛋白-1抑制剂

IF 0.9

Case Reports in Dermatology Pub Date : 2024-06-27 eCollection Date: 2024-01-01 DOI: 10.1159/000539592

Babette J A Verkouteren, An K L Reyners, Maureen J B Aarts, Klara Mosterd

{"title":"Hedgehog Pathway and Programmed Cell Death Protein-1 Inhibitors for Advanced Basal Cell Carcinoma.","authors":"Babette J A Verkouteren, An K L Reyners, Maureen J B Aarts, Klara Mosterd","doi":"10.1159/000539592","DOIUrl":"10.1159/000539592","url":null,"abstract":"Introduction: Basal cell carcinoma (BCC) is treated with local surgery or noninvasive treatment modalities. If a BCC remains untreated, it can develop into a locally advanced BCC or a metastatic BCC.Case presentation: Here we report in detail the management of three complex advanced BCC (aBCC) after treatment failure with vismodegib. On all tumors, next generation DNA sequencing in the Center for Personalized Cancer Treatment-02 (CPCT-02) study was performed; subsequently, patients were included in the Drug Rediscovery Protocol (DRUP) trial, in which treatment was started with commercially available targeted anticancer drugs based on the molecular tumor profile. All patients showed partial response or stable disease following treatment with second line PD-1 inhibitors with an average duration of response of 12.3 months.Discussion/conclusion: Immunotherapy can be a treatment option for aBCC resistant to hedgehog pathway inhibitor treatment. However, despite the high tumor mutational burden of aBCCs, immunotherapy does not always lead to a long response. Rechallenge or combining treatment of hedgehog inhibitors and PD-1 inhibitors by parallel or alternating cycles may be a strategy to lengthen the treatment response.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recalcitrant Basal Cell Carcinoma after Grenz Ray Therapy: Introduction of High-Intensity Focused Ultrasound for Minimally Invasive Management. 格林兹射线治疗后复发的基底细胞癌：引入高强度聚焦超声进行微创治疗。

IF 0.9

Case Reports in Dermatology Pub Date : 2024-06-27 eCollection Date: 2024-01-01 DOI: 10.1159/000539722

Jørgen Serup, Tomasz Zawada, Torsten Bove

{"title":"Recalcitrant Basal Cell Carcinoma after Grenz Ray Therapy: Introduction of High-Intensity Focused Ultrasound for Minimally Invasive Management.","authors":"Jørgen Serup, Tomasz Zawada, Torsten Bove","doi":"10.1159/000539722","DOIUrl":"10.1159/000539722","url":null,"abstract":"Introduction: Grenz ray therapy popular in dermatology decades ago causes multiple and recalcitrant skin cancer in the treated field many years later. The treatment of choice is surgical excision, but limitations especially disfiguring scarring are a major challenge. We introduce 20 MHz high-intensity focused ultrasound (HIFU) as a new therapy overcoming the limitations of excisional surgery.Case presentation: A 66-year-old female, who in the 1980s had received several grenz ray treatments of the scalp, developed multiple basal cell carcinomas in the field. She had over 30 excisional surgeries including Mohs surgery in the past with many local complications but, nevertheless, recurrent cancers. HIFU treatments applied to eight basal cell carcinomas and two precancerous lesions resulted in complete clearing at 12-month control, but one recurrence after 15 months.Conclusion: The HIFU treatment is convenient, with very few complications, and applicable to field eradication of skin premalignancies and malignancies. HIFU may fill out a hitherto unmet need of both preventive and curative treatment with better long-term control of patients with recalcitrant skin cancer after grenz ray given in the past. HIFU is a new potentially important therapeutic modality in skin oncology, combining curative treatment, field eradication, and prevention in one procedure through treatment of lesions in different states of progression.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pilomatrix Carcinoma: A Benign-Mimic with Malignant Consequences - A Case Report and Review of the Current Literature. 乳头状瘤：一种具有恶性后果的良性仿真瘤--病例报告和当前文献综述。

IF 0.9

Case Reports in Dermatology Pub Date : 2024-06-18 eCollection Date: 2024-01-01 DOI: 10.1159/000539123

Cedar A Slovacek, Yang Li, Maria Hurley, Ramona Beshad, Michael L Bernstein

{"title":"Pilomatrix Carcinoma: A Benign-Mimic with Malignant Consequences - A Case Report and Review of the Current Literature.","authors":"Cedar A Slovacek, Yang Li, Maria Hurley, Ramona Beshad, Michael L Bernstein","doi":"10.1159/000539123","DOIUrl":"10.1159/000539123","url":null,"abstract":"Introduction: Pilomatrix carcinomas (PMXCs) are uncommon, locally aggressive tumors with high recurrence rates, metastatic potential, and fewer than 130 cases reported in the literature. Typically, they present as an unassuming, firm, dermal swelling and therefore are frequently mistaken for more common, benign masses, leading to undertreatment which can cause local invasion and metastatic spread. Diagnosis relies on excision with pathologic analysis; however once diagnosed, there are no current recommendations to guide treatment or surveillance for recurrence or metastases.Case presentation: Here, we present a case of one of these rare tumors. Our case describes a 1.5 × 2.5 cm firm, mobile mass at the supraorbital rim in an otherwise healthy, young patient. Prior to removal, we suspected a benign pathology; however, excision proved difficult and pathologic diagnosis was consistent with PMXC. Following discussion with tumor board, decision was made to perform Mohs micrographic surgery and staging via CT scans with regular follow-up and surveillance scans.Conclusion: PMXCs are exceedingly rare diagnoses and present like many benign lesions. Therefore, we elected to document this case to encourage providers to keep these biologically aggressive tumors on their list of differential diagnoses in an unsuspecting mass, as well as to provide our own recommendations for treatment and screening for recurrence and metastatic spread.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrence of Quadruple Extramammary Paget's Disease after 12 Years: A Case Report and Literature Review. 12 年后复发的四联乳腺外 Paget 病：病例报告与文献综述

IF 0.9

Case Reports in Dermatology Pub Date : 2024-06-17 eCollection Date: 2024-01-01 DOI: 10.1159/000538675

Akihiro Ishiguro, Nobuhiko Iwashita, Michihiro Abe, Akina Ogawa, Tomohiro Takeo, Daisuke Watanabe

{"title":"Recurrence of Quadruple Extramammary Paget's Disease after 12 Years: A Case Report and Literature Review.","authors":"Akihiro Ishiguro, Nobuhiko Iwashita, Michihiro Abe, Akina Ogawa, Tomohiro Takeo, Daisuke Watanabe","doi":"10.1159/000538675","DOIUrl":"10.1159/000538675","url":null,"abstract":"Introduction: Extramammary Paget's disease (EMPD) is a rare skin cancer that tends to be multicentric, with quadruple EMPD cases being scarcely reported.Case presentation: We report the case of an 81-year-old man with heterochronous quadruple EMPD. Twelve years after total resection of vulvar EMPD, the patient developed erythematous lesions on the resection margin in the lower abdomen, umbilical region, and both axillae. Histological examination revealed that all lesions were in situ EMPD.Discussion: We reviewed six reported cases of quadruple EMPD with respect to race, sex, site, recurrence, time to recurrence, serum carcinoembryonic antigen, and depth. All patients were elderly Japanese males. In all but one case, the lesions were located in the apocrine region, which is a common site in such as the genital and axillary areas. Our case was the only heterochronous quadruple EMPD. The lesions were limited to the epidermis; therefore, they were unlikely to cause metastasis. It has been reported that the therapeutic effects of imiquimod can be expected in in situ EMPD. Therefore, quadruple EMPD may be a good indication of treatment option.Conclusion: EMPD is a disease whose pathogenesis is not yet clear; however, it is hoped that the origin and aetiology of EMPD will be elucidated from the clinical features of multiple EMPD in the future.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Janus Kinase Inhibitors as Successful Treatment Alternative in Dupilumab-Induced Psoriasis. Janus 激酶抑制剂作为杜匹单抗诱发的银屑病的成功替代治疗方案。

IF 0.9

Case Reports in Dermatology Pub Date : 2024-06-17 eCollection Date: 2024-01-01 DOI: 10.1159/000539124

Lina Weiss, Corinne Punsap Marbet, Lorenzo Barino Branca, Beda Mühleisen, Alexander Navarini

{"title":"Janus Kinase Inhibitors as Successful Treatment Alternative in Dupilumab-Induced Psoriasis.","authors":"Lina Weiss, Corinne Punsap Marbet, Lorenzo Barino Branca, Beda Mühleisen, Alexander Navarini","doi":"10.1159/000539124","DOIUrl":"10.1159/000539124","url":null,"abstract":"Introduction: After the introduction of dupilumab as systemic treatment for atopic dermatitis, an increasing number of patients have been successfully treated. However, reports of patients developing psoriasis as a secondary skin condition have been accumulating. The most likely reason is assumed to be an immune shift from Th2- to Th1-mediated auto-inflammatory processes.Case presentation: Our patient is a 38-year-old male suffering from head-neck type atopic dermatitis since childhood. As one of the first patients in Switzerland, he received dupilumab in 2018 leading to a significant improvement of his skin lesions. One year later he developed progressing circular erythematous-squamous plaques which correlated histologically with psoriasis. In 2021, 3 years after initiating dupilumab, we switched systemic therapy to baricitinib. Three months after initiation, his psoriatic lesions were completely healed, while the atopic lesions remained stable with low inflammatory activity.Conclusion: In patients treated with dupilumab for atopic dermatitis immune shift needs to be considered in case of newly appearing skin lesions. With a growing number of described cases, we conclude that baricitinib is a good alternative treatment for atopic dermatitis in patients suffering from biologic-induced psoriasis.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Porocarcinoma of the Groin: A Case Report. 腹股沟孔癌：病例报告。

IF 0.9

Case Reports in Dermatology Pub Date : 2024-06-12 eCollection Date: 2024-01-01 DOI: 10.1159/000539101

Hannah E Myers, Keith Pennycook, Joshua Hammel

引用次数: 0

Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report. 安可非尼、西妥昔单抗和比尼美替尼联合疗法中的爆发性黑素细胞痣：病例报告。

IF 0.9

Case Reports in Dermatology Pub Date : 2024-05-28 eCollection Date: 2024-01-01 DOI: 10.1159/000539058

Karen Lam, Gregory A Gates, Daniel Q Bach, Kyle Cheng

{"title":"Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report.","authors":"Karen Lam, Gregory A Gates, Daniel Q Bach, Kyle Cheng","doi":"10.1159/000539058","DOIUrl":"10.1159/000539058","url":null,"abstract":"Introduction: The development of new and changing melanocytic lesions has been increasingly reported as an adverse dermatologic toxicity of BRAF inhibitor therapy. Melanocytic lesions and melanomas induced by BRAF inhibitor therapy that lack BRAF V600E expression have been less commonly described. One mechanism that has been proposed for the development of BRAF inhibitor-induced melanocytic lesions, including those lacking BRAF V600E expression, is the paradoxical activation of the MAPK signaling pathway in BRAF wild-type (BRAFWT) cells.Case presentation: Herein, we report a rare case of a 39-year-old woman who developed numerous BRAF V600E-negative eruptive melanocytic nevi following encorafenib, cetuximab, and binimetinib combination therapy, the current standard of care for the treatment of BRAF-mutant metastatic colorectal cancer.Conclusion: Patients treated with BRAF inhibitors, with or without related combination therapies, who develop BRAFWT melanocytic lesions are at risk for developing both dysplastic nevi and melanoma, thereby warranting baseline dermatoscopic evaluation prior to the initiation of therapy as well as regular follow-up during and after treatment.","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11147515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0